Projektbeschreibung
Ein Medikament gegen Multiple Sklerose bei Herzinsuffizienz
Koronare Herzkrankheiten sind die häufigste Todesursache in Industrieländern mit Millionen Fällen allein in Europa. Sie sind mit einer verminderten Durchblutung des Herzens verbunden, die zum Herzinfarkt führen kann. Um die Herzmuskelreparatur anzugehen, die nach einem Herzinfarkt das Hauptproblem darstellt, wird das EU-finanzierte Projekt ReDHeaD das von der amerikanischen Arzneimittelbehörde FDA zugelassene Medikament Copaxon testen, das zur Behandlung von Multipler Sklerose eingesetzt wird. Präklinische Daten zeigen nach der Verabreichung von Copaxon eine signifikante Verbesserung der Herzfunktionsparameter. Das Forschungsteam plant die Vorbereitung klinischer Studien, um die Wirksamkeit des Arzneimittels beim Menschen zu validieren, und alle erforderlichen regulatorischen und kommerziellen Aktivitäten für dessen schnelle klinische Umsetzung durchzuführen.
Ziel
Coronary Heart Disease (CHD) and particularly Myocardial Infarction (MI), i.e. heart attack, is the leading cause of death in the Western world today. The main cause for CHD is the incapacity of the mammalian heart to undergo regeneration after injury. Current therapies are not able to address the central problem of decreased pumping capacity that results from the depleted pool of cardiac muscle cells. The outcome of this shortcoming is grim; nearly half of all patients with heart failure die within five years of the initial diagnosis.
We have tested a widely used FDA approved drug, Copaxone, which is used to treat Multiple Sclerosis, for its efficacy in heart repair and made a breakthrough discovery. Copaxone improved cardiac function and reduced scarring in a mouse MI model. Most of the treated mice (85%) responded to the treatment, exhibiting an average improvement of 44% in heart function parameters, along with 40% reduction in scar size.
In this PoC, we will expand these experiments by testing Copaxone using a chronic heart failure (CHF) model in both small and large animals (rats, pigs), and determine the optimal dosage regimen. Based on positive findings in this PoC, we plan to pursue Phase II clinical trials. The suggested activities include the preparation of the commercialization by interacting with key opinion leaders (e.g. cardiologists), who are in the position to speed up the clinical translation. We will also interact with pharma companies to build a potential collaborator and customer network. Eventually, we aim at commercializing repurposing existing drug to treat heart diseases, for CHF or acute MI indications. The impact of such therapy would be vast: CHD is the most common cause of death in Europe, accounting for 1.8 million deaths each year. As the original drug was already successfully commercialized by our institute, we can build on this experience and have the treatment available in approximately 5-6 years.
Wissenschaftliches Gebiet
Programm/Programme
Thema/Themen
Finanzierungsplan
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotGastgebende Einrichtung
7610001 Rehovot
Israel